Magnetic Resonance Imaging (MRI) to Predict Outcomes of Pancreatic Ductal Adenocarcinoma (PDAC)

MRI Imaging to Predict Outcomes of Treatment in PDAC Patients

The purpose of this study is to assess if Six-Dimensional Magnetic Resonance Imaging (6D-MRI) is effective in predicting outcomes in patients with pancreatic ductal adenocarcinoma (PDAC).

The overarching goal of this pilot study is to evaluate the usefulness of a novel Magnetic Resonance Imaging (MRI) approach, which measure properties of tumor microenvironment (i.e. vascularity, fibrosis), to predict PDAC response to neoadjuvant therapy (NAT).

Inclusion Criteria:

• Pancreatic cancer patients (with resectable or borderline resectable or locally advanced tumors) who will undergo neoadjuvant chemotherapy
• Patients able to undergo at least two sets of MRI sessions

Exclusion Criteria:

• Patients who have previously been treated for PDAC
• Patients unable to undergo MRI exam w/contrast
• Patients with metastatic pancreatic cancer visualized on index diagnostic imaging
• Patients with certain metallic implants
• Patients experiencing claustrophobia
• Persons with allergy to animal dander or animal-instigated asthma